Candel Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 42
- Market Cap
- -
- Website
- http://www.candeltx.com
- Introduction
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04495153
- Locations
- 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03131037
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT02768363
- Locations
- 🇺🇸
Foothills Urology, Golden, Colorado, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Allegheny Health Network-Triangle Urological Group, Pittsburgh, Pennsylvania, United States
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02446093
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
🇺🇸Lee Health/Regional Cancer Center, Fort Myers, Florida, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01997190
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 711
- Registration Number
- NCT01436968
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸21st Century Oncology, Plantation, Florida, United States
🇺🇸VA Maryland Health Care System, Baltimore, Maryland, United States
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00751270
- Locations
- 🇺🇸
The Ohio State University Medical Center, Dept Neurosurgery, Columbus, Ohio, United States
🇺🇸The Methodist Hosptial, Houston, Texas, United States
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
- Conditions
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00638612
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Scripps Green Hospital/Scripps Cancer Center, La Jolla, California, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00634231
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital), Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00589875
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸The Ohio State University Medical Center, Dept. Neurological Surgery, Columbus, Ohio, United States